The lifting of twenty-four million euros announced by ShanX Medtech does not only stand out for its amount, but above all highlights a growing gap between the traditional tools of venture capital and the economic, regulatory and industrial realities of critical medtech. As certain health technologies become health infrastructures in their own right, their financing ceases to obey the logic of the software.
Software as an implicit matrix of venture capital
For around fifteen years, venture capital has been structured around the dominant model of software with low marginal costs, scalable quickly, lightly regulated and capable of reaching a global market without heavy industrial investments. In this framework, risk is assumed early, traction takes precedence over profitability, and capital finances speed above all.
This model has shaped investors’ reading grids, their return expectations, and their exit horizons. It works as long as the product can be iterated quickly, deployed without hardware friction, and released before any major regulatory constraints. Except critical medtech does not check any of these boxes.
Long, expensive and irreducible cycles
In medical diagnosis, and even more so when it concerns systemic issues such as antibiotic resistance, time is not compressible. Technological development precedes clinical validation, which precedes regulatory approval. Approval itself conditions access to the market. Each step therefore mobilizes capital, rare skills and years of work.
ShanX Medtech illustrates this reality. Its antimicrobial technology aims to produce results in less than an hour, where current methods require several days. A clinical breakthrough, but whose value cannot be captured without robust scientific demonstration, clinical trials, regulatory compliance control and its integration into care pathways.
In medtech, unlike a software product, there is no “beta version” that can be deployed on a large scale to test the market and the risk must be absorbed upstream, well before the first significant revenues.
When venture capital alone is no longer enough
This is precisely what the financial structuring of ShanX Medtech reveals. Among my fifteen million euros seed funds obtained, all of them do not come only from venture capital funds, but from a combination of equity, subsidies and national public schemes. To this is added a European contract worth 8.8 million eurosawarded via HERA and HADEA, bringing the total funding to twenty-four million euros.
This arrangement reflects the impossibility, for classic venture capital, of taking on such long cycles alone without risk sharing mechanisms, and public intervention makes it possible.
The profile of the investors involved, whether these funds, public players, or vehicles linked to a health insurer, demonstrates an alignment of interests around an issue that goes beyond financial performance alone.
From startup to health infrastructure
The other critical point relates to the very nature of these technologies. The rapid diagnosis of antimicrobial resistance is not a simple product, it must be considered as a lever for steering the healthcare system: guiding prescriptions, reducing hospital stays, controlling costs, preventing pandemics caused by antimicrobial resistance.
By financing ShanX Medtech via HERA, the European Commission implicitly recognizes this change in status and recognizes the diagnosis as a strategic health infrastructure, in the same way as vaccine production capacities or pharmaceutical supply chains.
However, an infrastructure cannot be financed like SaaS; it requires patient capital, public-private coordination, and return horizons compatible with long-term issues.
A broader change in health financing
The ShanX case is all the less isolated as it is part of a broader movement where certain health verticals (diagnostics, bioproduction, critical medical devices) are gradually leaving the mental framework inherited from consumer tech.
This development requires a change in posture for founders, who must prove their ability to achieve clinical, regulatory and industrial milestones.
Towards a new contract between innovation and capital
The question is therefore not whether critical medtech is less “scalable” than software, but whether the financing tools are adapted to technologies which produce systemic value before producing turnover.
Founded in 2019 and based in Eindhoven, in the heart of the High Tech Campus, ShanX Medtech is developing an in vitro diagnostic platform dedicated to ultra-rapid antimicrobial susceptibility testing. Led by its founder and CEO, Dr. Sophia E. Shankothe company relies on technology for measuring microbial metabolism making it possible to obtain clinically usable results in less than an hour, in the laboratory as well as at point-of-care. In January 2026, the company secured twenty-four million euros financing, combining an oversubscribed seed round of fifteen million euros led by Borski Fund, NextGen Ventures, CbusineZ, BOM and Invest-NL, and a European contract of eight million eight hundred and fifty thousand euros awarded via HERA and HADEA. These resources should make it possible to complete clinical validation, obtain regulatory authorizations and initiate the commercial launch of a technology positioned as a structuring lever in the fight against antibiotic resistance.
